The development of potential antibody-based therapies for myeloma

Blood Reviews

Volumn 29, Issue 2, 2015, Pages 81-91

  Sherbenou, Daniel W ^a,b   Behrens, Christopher R ^a   Su, Yang ^a   Wolf, Jeffrey L ^a,b   Martin, Thomas G ^a,b   Liu, Bin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody drug conjugate; Immunotherapy; Monoclonal antibodies; Multiple myeloma; Plasma cell myeloma; Targeted cancer therapy

Indexed keywords

ANTIBODY CONJUGATE; AVE 1642; BRENTUXIMAB VEDOTIN; CD38 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CD74 ANTIGEN; DACETUZUMAB; DARATUMUMAB; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; FC RECEPTOR; FIGITUMUMAB; GEMTUZUMAB OZOGAMICIN; INDATUXIMAB RAVTANSINE; INTERLEUKIN 6; ISATUXIMAB; LENALIDOMIDE; LORVOTUZUMAB MERTANSINE; LUCATUMUMAB; MILATUZUMAB; NIVOLUMAB; PIDILIZUMAB; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; SILTUXIMAB; SOMATOMEDIN C RECEPTOR; SYNDECAN 1; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ACUTE MYELOBLASTIC LEUKEMIA; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASEPTIC MENINGITIS; BLURRED VISION; BRADYCARDIA; CANCER GROWTH; CANCER IMMUNOTHERAPY; CHILL; CLINICAL EFFECTIVENESS; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOKINE RELEASE SYNDROME; DRUG APPROVAL; DRUG SAFETY; DRY EYE; EYE INFLAMMATION; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; INFUSION RELATED REACTION; KIDNEY FAILURE; LIVER TOXICITY; MELANOMA; METASTATIC MELANOMA; MUCOSA INFLAMMATION; MYELOMA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REFLEX DISORDER; REVIEW; SMALL CELL LUNG CANCER; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WEAKNESS; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; MULTIPLE MYELOMA; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; MULTIPLE MYELOMA;

EID: 84933177886     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.09.011     Document Type: Article

References (112)

1. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008, 59:237-250.
2. Plosker G.L., Figgitt D.P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003, 63(8):803-843.
3. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov Oct 2010, 9(10):767-774.
4. Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol Off J Am Soc Clin Oncol Jun 20 2012, 30(18):2183-2189.
5. Pro B., Advani R., Brice P., Bartlett N.L., Rosenblatt J.D., Illidge T., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol Jun 20 2012, 30(18):2190-2196.
6. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res Nov 15 2008, 68(22):9280-9290.
7. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med Nov 8 2012, 367(19):1783-1791.
8. Hurvitz S.A., Dirix L., Kocsis J., Bianchi G.V., Lu J., Vinholes J., et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol Mar 20 2013, 31(9):1157-1163.
9. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer Apr 2012, 12(4):278-287.
10. Lopez-Girona A., Mendy D., Ito T., Miller K., Gandhi A.K., Kang J., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia Nov 2012, 26(11):2326-2335.
11. Zhu Y.X., Braggio E., Shi C.-X., Bruins L.A., Schmidt J.E., Wier S.V., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood Nov 3 2011, 118(18):4771-4779.
12. Lu G., Middleton R.E., Sun H., Naniong M., Ott C.J., Mitsiades C.S., et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science Jan 17 2014, 343(6168):305-309.
13. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood Jun 15 2006, 107(12):4907-4916.
14. Jain R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res Feb 1 1990, 50(Suppl. 3):814s-819s.
15. Tabrizi M., Bornstein G.G., Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J Nov 19 2009, 12(1):33-43.
16. Tai Y.-T., Anderson K.C. Antibody-based therapies in multiple myeloma. Bone Marrow Res 2011, 2011:924058.
17. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science Jan 9 1987, 235(4785):177-182.
18. Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell Feb 7 1992, 68(3):421-427.
19. Falini B., Pileri S., Pizzolo G., Dürkop H., Flenghi L., Stirpe F., et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood Jan 1 1995, 85(1):1-14.
20. Ansell S.M., Horwitz S.M., Engert A., Khan K.D., Lin T., Strair R., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol Jul 1 2007, 25(19):2764-2769.
21. Forero-Torres A., Leonard J.P., Younes A., Rosenblatt J.D., Brice P., Bartlett N.L., et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol Jul 2009, 146(2):171-179.
22. Bander N.H. Antibody-drug conjugate target selection: critical factors. Methods Mol Biol Clifton NJ 2013, 1045:29-40.
23. Erickson H.K., Park P.U., Widdison W.C., Kovtun Y.V., Garrett L.M., Hoffman K., et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res Apr 15 2006, 66(8):4426-4433.
24. Doronina S.O., Mendelsohn B.A., Bovee T.D., Cerveny C.G., Alley S.C., Meyer D.L., et al. Enhanced activity of monomethylauristatin f through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem Jan 2006, 17(1):114-124.
25. Leo R., Boeker M., Peest D., Hein R., Bartl R., Gessner J.E., et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol Mar 1992, 64(3):132-139.
26. Bataille R., Jégo G., Robillard N., Barillé-Nion S., Harousseau J.-L., Moreau P., et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica Sep 2006, 91(9):1234-1240.
27. Pellat-Deceunynck C., Bataille R., Robillard N., Harousseau J.L., Rapp M.J., Morineau N.J.-, et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood Oct 15 1994, 84(8):2597-2603.
28. Sanderson R.D., Lalor P., Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul Nov 1989, 1(1):27-35.
29. Hayashi K., Hayashi M., Jalkanen M., Firestone J.H., Trelstad R.L., Bernfield M. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J Histochem Cytochem Off J Histochem Soc Oct 1987, 35(10):1079-1088.
30. Nguyen T.L., Grizzle W.E., Zhang K., Hameed O., Siegal G.P., Wei S. Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. Am J Clin Pathol Oct 2013, 140(4):468-474.
31. Van Camp B., Durie B.G., Spier C., De Waele M., Van Riet I., Vela E., et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood Jul 15 1990, 76(2):377-382.
32. Pellat-Deceunynck C., Barillé S., Puthier D., Rapp M.J., Harousseau J.L., Bataille R., et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res Aug 15 1995, 55(16):3647-3653.
33. Pellat-Deceunynck C., Barillé S., Jego G., Puthier D., Robillard N., Pineau D., et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia Dec 1998, 12(12):1977-1982.
34. Abo T., Balch C.M. A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol Sep 1981, 127(3):1024-1029. (Baltim Md 1950).
35. Lanier L.L., Le AM Ding A., Evans E.L., Krensky A.M., Clayberger C., et al. Expression of Leu-19 (NKH-1) antigen on IL 2-dependent cytotoxic and non-cytotoxic T cell lines. J Immunol Apr 1 1987, 138(7):2019-2023. (Baltim Md 1950).
36. Mechtersheimer G., Staudter M., Möller P. Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. Cancer Res Feb 15 1991, 51(4):1300-1307.
37. Burton J.D., Ely S., Reddy P.K., Stein R., Gold D.V., Cardillo T.M., et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res Off J Am Assoc Cancer Res Oct 1 2004, 10(19):6606-6611.
38. Wraight C.J., van Endert P., Möller P., Lipp J., Ling N.R., MacLennan I.C., et al. Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem Apr 5 1990, 265(10):5787-5792.
39. Claesson-Welsh L., Scheynius A., Tjernlund U., Peterson P.A. Cell surface expression of invariant gamma-chain of class II histocompatibility antigens in human skin. J Immunol Jan 1986, 136(2):484-490. (Baltim Md 1950).
40. Hansen H.J., Ong G.L., Diril H., Valdez A., Roche P.A., Griffiths G.L., et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J Nov 15 1996, 320(Pt 1):293-300.
41. Ong G.L., Goldenberg D.M., Hansen H.J., Mattes M.J. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology Oct 1999, 98(2):296-302.
42. Uckun F.M., Gajl-Peczalska K., Myers D.E., Jaszcz W., Haissig S., Ledbetter J.A. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood Dec 15 1990, 76(12):2449-2456.
43. Mach F., Schönbeck U., Sukhova G.K., Bourcier T., Bonnefoy J.-Y., Pober J.S., et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci Mar 4 1997, 94(5):1931-1936.
44. Westendorf J.J., Ahmann G.J., Armitage R.J., Spriggs M.K., Lust J.A., Greipp P.R., et al. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol Jan 1 1994, 152(1):117-128. (Baltim Md 1950).
45. Bataille R., Robillard N., Avet-Loiseau H., Harousseau J.-L., Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica May 2005, 90(5):706-707.
46. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell Mar 2004, 5(3):221-230.
47. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev Apr 1995, 16(2):143-163.
48. Hsi E.D., Steinle R., Balasa B., Szmania S., Draksharapu A., Shum B.P., et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res May 1 2008, 14(9):2775-2784.
49. Tai Y.-T., Dillon M., Song W., Leiba M., Li X.-F., Burger P., et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood Aug 15 2008, 112(4):1329-1337.
50. Murphy J.J., Hobby P., Vilarino-Varela J., Bishop B., Iordanidou P., Sutton B.J., et al. A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion. Biochem J Feb 1 2002, 361(Pt 3):431-436.
51. Davis R.S., Wang Y.H., Kubagawa H., Cooper M.D. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U S A Aug 14 2001, 98(17):9772-9777.
52. Elkins K., Zheng B., Go M., Slaga D., Du C., Scales S.J., et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther Oct 2012, 11(10):2222-2232.
53. Ise T., Nagata S., Kreitman R.J., Wilson W.H., Wayne A.S., Stetler-Stevenson M., et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia Jan 2007, 21(1):169-174.
54. Novak A.J., Darce J.R., Arendt B.K., Harder B., Henderson K., Kindsvogel W., et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood Jan 15 2004, 103(2):689-694.
55. Neri P., Kumar S., Fulciniti M.T., Vallet S., Chhetri S., Mukherjee S., et al. Neutralizing B-cell-activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res Oct 1 2007, 13(19):5903-5909.
56. Carpenter R.O., Evbuomwan M.O., Pittaluga S., Rose J.J., Raffeld M., Yang S., et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res Apr 15 2013, 19(8):2048-2060.
57. Tai Y.-T., Mayes P.A., Acharya C., Zhong M.Y., Cea M., Cagnetta A., et al. Novel afucosylated anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity. Blood May 15 2014, 123(20):3128-3138.
58. Doronina S.O., Toki B.E., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Chace D.F., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol Jul 2003, 21(7):778-784.
59. Hills R.K., Petersdorf S., Estey E.H., Othus M., Appelbaum F.R., Castaigne S., et al. The addition of gemtuzumab ozogamicin (GO) to induction chemotherapy reduces relapse and improves survival in patients without adverse risk karyotype: results of an individual patient meta-analysis of the five randomised trials. Blood Nov 15 2013, 122(21). (Abstract 356).
60. Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol Jul 2012, 30(7):631-637.
61. Ikeda H., Hideshima T., Fulciniti M., Lutz R.J., Yasui H., Okawa Y., et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res Off J Am Assoc Cancer Res Jun 15 2009, 15(12):4028-4037.
62. Teicher B.A., Chari R.V.J. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res Oct 15 2011, 17(20):6389-6397.
63. Tassone P., Gozzini A., Goldmacher V., Shammas M.A., Whiteman K.R., Carrasco D.R., et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res Jul 1 2004, 64(13):4629-4636.
64. Sapra P., Stein R., Pickett J., Qu Z., Govindan S.V., Cardillo T.M., et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res Off J Am Assoc Cancer Res Jul 15 2005, 11(14):5257-5264.
65. Durie B.G.M., Harousseau J.-L., Miguel J.S., Bladé J., Barlogie B., Anderson K., et al. International uniform response criteria for multiple myeloma. Leukemia Sep 2006, 20(9):1467-1473.
66. Bladé J., Samson D., Reece D., Apperley J., Björkstrand B., Gahrton G., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT European Group for Blood and Marrow Transplant. Br J aematol Sep 1998, 102(5):1115-1123.
67. De Weers M., Tai Y.-T., van der Veer M.S., Bakker J.M., Vink T., Jacobs D.C.H., et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol Feb 1 2011, 186(3):1840-1848. (Baltim Md 1950).
68. Plesner T., Lokhorst H., Gimsing P., Nahi H., Lisby S., Richardson P.G. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I/II study. Blood Nov 16 2012, 120(21). (Abstract 73).
69. Martin T.G., Strickland S.A., Glenn M., Zheng W., Daskalakis N., Mikhael J.R. SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies - data from a dose-escalation phase I study. Blood Nov 15 2013, 122(21). (Abstract 284).
70. Martin T.G., Hsu K., Charpentier E., Vij R., Baz R.C., Benson D.M., et al. A phase Ib dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. ASCO Meet Abstr Jun 11 2014, 32(Suppl. 15). (Abstract 8512).
71. Wetzel M.-C., Nicolazzi C., Vallee F., Deckert J., Dumontet C., Plesa A., et al. Abstract 4735: SAR650984: characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies. Cancer Res Aug 14 2013, 73(Suppl. 8). (Abstract 4735).
72. Veillette A., Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol Oct 2013, 88(1):168-177.
73. Zonder J.A., Mohrbacher A.F., Singhal S., van Rhee F., Bensinger W.I., Ding H., et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood Jul 19 2012, 120(3):552-559.
74. Jakubowiak A.J., Benson D.M., Bensinger W., Siegel D.S.D., Zimmerman T.M., Mohrbacher A., et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol Jun 1 2012, 30(16):1960-1965.
75. Lonial S., Jagannath S., Moreau P., Jakubowiak A.J., Raab M.S., Facon T., et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety. ASCO Meet Abstr Jun 17 2013, 31(Suppl. 15). (Abtract 8542).
76. Tai Y.-T., Catley L.P., Mitsiades C.S., Burger R., Podar K., Shringpaure R., et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res Apr 15 2004, 64(8):2846-2852.
77. Hussein M., Berenson J.R., Niesvizky R., Munshi N., Matous J., Sobecks R., et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica May 2010, 95(5):845-848.
78. Agura E., Niesvizky R., Matous J., Munshi N., Hussein M., Parameswaran R.V., et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase 1b study. Blood Nov 20 2009, 114(22). (Abstract 2870).
79. Bensinger W., Maziarz R.T., Jagannath S., Spencer A., Durrant S., Becker P.S., et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol Oct 2012, 159(1):58-66.
80. Kaufman J.L., Niesvizky R., Stadtmauer E.A., Chanan-Khan A., Siegel D., Horne H., et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol Nov 2013, 163(4):478-486.
81. Sprynski A.C., Hose D., Caillot L., Réme T., Shaughnessy J.D., Barlogie B., et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood May 7 2009, 113(19):4614-4626.
82. Lacy M.Q., Alsina M., Fonseca R., Paccagnella M.L., Melvin C.L., Yin D., et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol Jul 1 2008, 26(19):3196-3203.
83. Moreau P., Cavallo F., Leleu X., Hulin C., Amiot M., Descamps G., et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia May 2011, 25(5):872-874.
84. Voorhees P.M., Chen Q., Kuhn D.J., Small G.W., Hunsucker S.A., Strader J.S., et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res Nov 1 2007, 13(21):6469-6478.
85. Voorhees P.M., Chen Q., Small G.W., Kuhn D.J., Hunsucker S.A., Nemeth J.A., et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol May 2009, 145(4):481-490.
86. Hardin J., MacLeod S., Grigorieva I., Chang R., Barlogie B., Xiao H., et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood Nov 1 1994, 84(9):3063-3070.
87. Van Zaanen H.C., Lokhorst H.M., Aarden L.A., Rensink H.J., Warnaar S.O., van der Lelie J., et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol Aug 1998, 102(3):783-790.
88. Kurzrock R., Voorhees P.M., Casper C., Furman R.R., Fayad L., Lonial S., et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res Off J Am Assoc Cancer Res Jul 1 2013, 19(13):3659-3670.
89. Voorhees P.M., Manges R.F., Sonneveld P., Jagannath S., Somlo G., Krishnan A., et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol May 2013, 161(3):357-366.
90. Jagannath S., Chanan-Khan A., Heffner L.T., Avigan D., Zimmerman T.M., Lonial S., et al. BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma. Blood Nov 18 2011, 118(21). (Abstract 305).
91. Kelly K.R., Chanan-Khan A., Somlo G., Heffner L.T., Siegel D.S., Zimmerman T.M., et al. Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in len/dex-refractory patients. Blood Nov 15 2013, 122(21). (Abstract 758).
92. Chanan-Khan A., Wolf J.L., Garcia J., Gharibo M., Jagannath S., Manfredi D., et al. Efficacy analysis from phase i study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma - a preliminary efficacy analysis. Blood Nov 19 2010, 116(21). (Abstract 1962).
93. Yong K.L., Germaschewski F.M., Rodriguez-Justo M., Bounds D., Lee L., Mayes P.A., et al. Evaluation Of BCMA as a therapeutic target in multiple myeloma using an antibody-drug conjugate. Blood Nov 15 2013, 122(21):4447.
94. Gattei V., Degan M., Gloghini A., Iuliis A.D., Improta S., Rossi F.M., et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood Mar 15 1997, 89(6):2048-2059.
95. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med Aug 25 2011, 365(8):725-733.
96. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368(16):1509-1518.
97. Davila M.L., Riviere I., Wang X., Bartido S., Park J., Curran K., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med Feb 19 2014, 6(224). (224ra25-224ra25).
98. Maus M.V., June C.H. Zoom Zoom: racing CARs for multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res Apr 15 2013, 19(8):1917-1919.
99. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol Off J Am Soc Clin Oncol Mar 3 2014, 32(10):1020-1030.
100. Liu J., Hamrouni A., Wolowiec D., Coiteux V., Kuliczkowski K., Hetuin D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood Jul 1 2007, 110(1):296-304.
101. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res May 15 2008, 14(10):3044-3051.
102. Rosenblatt J., Glotzbecker B., Mills H., Vasir B., Tzachanis D., Levine J.D., et al. PD-1 blockade by CT-011, anti PD-1 antibody, enhances ex-vivo T cell responses to autologous dendritic/myeloma fusion vaccine. J Immunother Jun 2011, 34(5):409-418. (Hagerstown Md 1997).
103. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol Off J Am Soc Clin Oncol Nov 15 2002, 20(22):4420-4427.
104. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood Nov 1 2002, 100(9):3063-3067.
105. Matsui W., Huff C.A., Wang Q., Malehorn M.T., Barber J., Tanhehco Y., et al. Characterization of clonogenic multiple myeloma cells. Blood Mar 15 2004, 103(6):2332-2336.
106. Huff C.A., Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol Off J Am Soc Clin Oncol Jun 10 2008, 26(17):2895-2900.
107. Tagoug I., Plesa A., Dumontet C. Bortezomib influences the expression of malignant plasma cells membrane antigens. Eur J Pharmacol Apr 15 2013, 706(1-3):11-16.
108. Panowksi S., Bhakta S., Raab H., Polakis P., Junutula J.R. Site-specific antibody drug conjugates for cancer therapy. MAbs Jan 1 2014, 6(1):34-45.
109. Behrens C.R., Liu B. Methods for site-specific drug conjugation to antibodies. mAbs Jan-Feb 2014, 6(1):46-53.
110. Vij R., Wang M., Kaufman J.L., Lonial S., Jakubowiak A.J., Stewart A.K., et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood Jun 14 2012, 119(24):5661-5670.
111. Schey S.A., Fields P., Bartlett J.B., Clarke I.A., Ashan G., Knight R.D., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol Aug 15 2004, 22(16):3269-3276.
112. Funaro A., Spagnoli G.C., Ausiello C.M., Alessio M., Roggero S., Delia D., et al. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J Immunol Oct 15 1990, 145(8):2390-2396. (Baltim Md 1950).